Related Experiment Video
Updated: May 6, 2026

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
Comparative Analysis of Additional Risk Minimization Measures in the Risk Management Plan in the European Union and
Teruyuki Honda1,2, Mamoru Narukawa1
1Department of Clinical Medicine (Pharmaceutical Medicine), Graduate School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan.
Japan implements additional risk minimization measures more broadly than the European Union, utilizing more extensive educational materials. These differences reflect distinct regulatory approaches to drug safety.
Area of Science:
- Pharmacovigilance and Regulatory Science
- International Drug Safety
- Risk Management in Pharmaceuticals
Background:
- Regulatory frameworks for medicinal products differ significantly between the European Union (EU) and Japan.
- Risk management plans (RMPs) include additional risk minimization measures (aRMMs) to address specific safety concerns.
- Understanding regional differences in aRMMs is crucial for global drug safety harmonization.
Purpose of the Study:
- To compare the implementation of aRMMs in the EU and Japan for concurrently approved medicinal products.
- To analyze the types of aRMMs, their coverage of safety concerns, and the characteristics of educational materials.
- To identify differences in regulatory approaches to drug safety between the EU and Japan.
Main Methods:
- Retrospective analysis of medicinal products approved in both the EU and Japan as of December 2023.
- Extraction and comparison of data on safety concerns, aRMMs, and educational materials for healthcare professionals and patients.
- Quantitative and qualitative assessment of aRMM prevalence, types, and educational material content.
Main Results:
- Additional risk minimization measures were present in 33.2% of EU products versus 73.0% of Japanese products.
- Direct healthcare professional communications were unique to the EU, while early post-marketing vigilance characterized Japan.
- Japanese educational materials were more extensive and covered more safety concerns compared to the targeted EU materials.
Conclusions:
- Japan employs a broader application of aRMMs with comprehensive educational materials, contrasting with the EU's selective, purpose-specific approach.
- Differences in aRMM strategies reflect distinct regulatory environments and healthcare systems.
- Optimizing aRMM strategies in Japan could improve risk mitigation and resource efficiency.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Relative Risk
Global Regulatory Systems
Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Drug Control Governance: Regulatory Bodies and Their Impact
Design Example: Analyzing Capacity Contours for Flood Risk Assessment
